Qiming Venture Partners Perspective: Deepening China Healthcare Innovation to Build Global Value Core
Let China's medical innovation achievements benefit the world, and make Chinese innovation a major driving force for global healthcare development.
Editor's Note: Today, China's healthcare innovation has steadily risen from its early industrial beginnings to become a central force in the global healthcare innovation landscape. Through industry cycles and market adjustments, it continues to iterate and upgrade, accelerating its advance into global markets through technological breakthroughs and ecosystem maturation. Against this backdrop, William Hu, Managing Partner at Qiming Venture Partners, was recently invited to contribute to Securities Times' venture capital Lunar New Year series. In his article, he reviews the industry's development trajectory, interprets the breakthroughs and achievements of Chinese healthcare innovation across three major domains — drug R&D, medical devices, and AI healthcare — and analyzes the core drivers and future trends shaping the industry.
This authorized republication comes from the Qiming Venture Partners WeChat official account.
Over the past two decades, China's healthcare innovation market has continuously evolved through industry waves, transforming from early industrial void to today's global innovation powerhouse. Behind this development lies the persistent drive of market demand, and more fundamentally, the gradual maturation and upgrading of China's healthcare innovation ecosystem. On one hand, the market has weathered cyclical challenges including valuation fluctuations and industry adjustments; on the other, leveraging China's unique industrial ecosystem advantages, cost and efficiency strengths, and a cohort of research and entrepreneurial teams possessing both international vision and localized execution capability, Chinese healthcare innovation is progressing from domestic breakthroughs to global output, becoming an indispensable component of the global healthcare innovation map.
William Hu, Managing Partner at Qiming Venture Partners
In drug R&D, Chinese innovation has long since shed its early follower model, achieving a transformation from building R&D ecosystems to domestic innovation breakthroughs, and onward to creating global value. Today's Chinese innovative drug companies boast clinical data for numerous R&D programs that rank among the global forefront, yielding multiple innovation achievements with Best-in-class potential, while the scale and depth of partnership and transaction activity with overseas pharmaceutical companies continues to deepen.
The innovative medical device sector is equally vibrant, with Chinese companies designing products that achieve global leadership in technology and user experience. From cardiovascular devices to single-use endoscopes, multiple products have been exported to over 100 countries and regions, entering tens of thousands of overseas hospitals, enabling Chinese-manufactured medical equipment to serve patients worldwide. In this context, investment institutions' deployment logic has also advanced — supporting portfolio companies to link global resources based on China's ecosystem as a foundation, which places higher demands on investors' industry understanding, global perspective, and post-investment capabilities.
Furthermore, the convergence of artificial intelligence and healthcare has become one of the core investment themes in healthcare for the coming decade. AI not only empowers critical links in new drug R&D such as target discovery and compound synthesis, but also plays an outsized role in cutting-edge domains including protein synthesis. Its impact on the healthcare industry is comprehensive and profound, and will continuously enhance the efficiency and innovation boundaries of medical R&D. Leveraging its cross-team synergies in technology and healthcare innovation, Qiming Venture Partners laid out early positions in AI healthcare applications, witnessing and participating in the process of AI transforming the healthcare innovation ecosystem.
From a macro perspective, China possesses continuously growing high-quality healthcare demand, deepening demographic aging trends, and globally leading healthcare R&D and manufacturing ecosystems. As fertile ground for healthcare innovation, its development potential is both long-term and certain — this is the core logic behind our steadfast commitment to the Chinese healthcare market.
From its launch of dedicated healthcare investment activities in 2006 to the present, Qiming Venture Partners has accompanied Chinese healthcare innovation through two decades — from investing in ecosystem-defining, leading enterprises such as Tigermed, Gan & Lee Pharmaceuticals, MicroPort EP, and Insilico Medicine, to building exchange platforms between portfolio companies and top global pharmaceutical companies for global innovation integration. We have always believed in the long-term value of Chinese healthcare innovation.
Going forward, we will continue to uphold the philosophy of "Chinese Innovation, Global Value," leveraging our deep understanding of China's healthcare ecosystem and rich industrial resources to identify high-quality healthcare enterprises with strong technological content and competitive moats, helping our portfolio companies leverage the best infrastructure worldwide, connecting with global partners, and driving more Chinese healthcare innovation into global value chains and industrial chains. Simultaneously, we will employ professional industry research, extensive project coverage, and mature investment methodology to seize trends amid the waves of healthcare innovation, navigate through cycles, extend the benefits of Chinese healthcare innovation achievements to the world, and make Chinese innovation an important driving force for global healthcare development.
Source | Securities Times
Editor | Yue Yanan
Proofreader | Tao Qian
Past Highlights
Qiming Honors | 5 Qiming Venture Partners Investors Named to 2025 Forbes China Midas List
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, Qiming has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative enterprises, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many companies in Qiming's portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Arbutus Biopharma, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, among others.